Exelixis (EXEL) stock forecast for 2022
Last update: December 5, 2022 (05:58)Sector: Healthcare
The share price of Exelixis, Inc. (EXEL) now
What analysts predict: $26.53
52-week high/low: $23.4 / $14.87
50/200 Day Moving Average: $16.39 / $19.32
This figure corresponds to the average price over the previous 50/200 days. For Exelixis stocks, the 50-day moving average is the support level today.
For Exelixis stocks, the 200-day moving average is the resistance level today.
Are you interested in Exelixis stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Exelixis stock price in 2022. How much will one Exelixis share be worth in 2022?
Is it worth taking profit / loss on Exelixis stock now or waiting? What are analysts' forecasts for Exelixis stock?
We forecast Exelixis stock performance using neural networks based on historical data on Exelixis stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
The Exelixis stock prediction results are shown below and presented as a graph, table and text information.
Exelixis stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Exelixis analysts is $26.53.
Today 200 Day Moving Average is the resistance level (19.32 $).
50 Day Moving Average is the support level (16.39 $).
Historical and forecast chart of Exelixis stock
The chart below shows the historical price of Exelixis stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Exelixis stock price can be found in the table below.
Exelixis (EXEL) Forecast for 2022
Exelixis information and performance
Exelixis, Inc. is a biotechnology company specializing in the development of promising low molecular weight drugs for the treatment of cancer and other serious diseases, including kidney damage, thyroid cancer and progressive melanoma. In addition, the company is forging strategic partnerships with other pharmaceutical and biotech companies.
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, US
Market Capitalization: 5 609 335 000 $
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA: 383 066 000 $
EBITDA is earnings before interest, income tax and depreciation of assets.
PE Ratio: 18.5
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
PEG Ratio: 0.329
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Quarterly Earnings Growth YOY: 0.894
Quarterly Revenue Growth YOY: 0.254
Trailing PE: 18.5
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward PE: 11.04
Forward P/E uses projections of future earnings instead of final numbers.
EV To Revenue: 2.577
Enterprise Value (EV) /Revenue
EV To EBITDA: 11.02
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Shares Outstanding: 322561000
Number of issued ordinary shares
Shares Float: N/A
Number of freely tradable shares
Shares Short Prior Month: N/A
Shares Short Prior Month - the number of shares in short positions in the last month.
Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A
Exelixis price target for 2022 by month
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.